vs
Coherus Oncology, Inc.（CHRS）与Digimarc CORP（DMRC）财务数据对比。点击上方公司名可切换其他公司
Coherus Oncology, Inc.的季度营收约是Digimarc CORP的1.4倍（$12.7M vs $8.9M），Digimarc CORP净利率更高（-47.2% vs -295.3%，领先248.1%），Coherus Oncology, Inc.同比增速更快（64.9% vs 2.9%），过去两年Digimarc CORP的营收复合增速更高（-5.3% vs -47.0%）
Coherus Oncology是一家处于商业化阶段的生物制药企业，专注于肿瘤领域药物的研发、生产与商业化，产品包括肿瘤生物类似药、新型靶向免疫肿瘤疗法，主要面向北美市场，致力于提升癌症患者平价创新治疗方案的可及性。
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
CHRS vs DMRC — 直观对比
营收规模更大
CHRS
是对方的1.4倍
$8.9M
营收增速更快
CHRS
高出62.0%
2.9%
净利率更高
DMRC
高出248.1%
-295.3%
两年增速更快
DMRC
近两年复合增速
-47.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.7M | $8.9M |
| 净利润 | $-37.6M | $-4.2M |
| 毛利率 | 68.3% | 63.5% |
| 营业利润率 | -359.9% | -48.2% |
| 净利率 | -295.3% | -47.2% |
| 营收同比 | 64.9% | 2.9% |
| 净利润同比 | 25.7% | 51.4% |
| 每股收益（稀释后） | $-0.34 | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHRSDMRC
| Q4 25 | $12.7M | $8.9M | ||
| Q3 25 | $11.6M | $7.6M | ||
| Q2 25 | $10.3M | $8.0M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | $10.3M | $10.4M | ||
| Q1 24 | — | $9.9M |
净利润CHRSDMRC
| Q4 25 | $-37.6M | $-4.2M | ||
| Q3 25 | $-35.5M | $-8.2M | ||
| Q2 25 | $297.8M | $-8.2M | ||
| Q1 25 | — | $-11.7M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | — | $-10.8M | ||
| Q2 24 | $-12.9M | $-9.3M | ||
| Q1 24 | — | $-10.3M |
毛利率CHRSDMRC
| Q4 25 | 68.3% | 63.5% | ||
| Q3 25 | 67.8% | 58.3% | ||
| Q2 25 | 66.9% | 58.8% | ||
| Q1 25 | — | 65.0% | ||
| Q4 24 | — | 60.8% | ||
| Q3 24 | — | 62.4% | ||
| Q2 24 | 82.4% | 66.1% | ||
| Q1 24 | — | 62.5% |
营业利润率CHRSDMRC
| Q4 25 | -359.9% | -48.2% | ||
| Q3 25 | -383.1% | -109.7% | ||
| Q2 25 | -443.6% | -105.2% | ||
| Q1 25 | — | -128.9% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -120.4% | ||
| Q2 24 | -384.9% | -96.2% | ||
| Q1 24 | — | -109.2% |
净利率CHRSDMRC
| Q4 25 | -295.3% | -47.2% | ||
| Q3 25 | -307.1% | -106.9% | ||
| Q2 25 | 2903.9% | -102.6% | ||
| Q1 25 | — | -125.2% | ||
| Q4 24 | — | -99.9% | ||
| Q3 24 | — | -113.9% | ||
| Q2 24 | -125.5% | -89.3% | ||
| Q1 24 | — | -104.0% |
每股收益（稀释后）CHRSDMRC
| Q4 25 | $-0.34 | $-0.18 | ||
| Q3 25 | $-0.31 | $-0.38 | ||
| Q2 25 | $2.57 | $-0.38 | ||
| Q1 25 | — | $-0.55 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | — | $-0.50 | ||
| Q2 24 | $-0.11 | $-0.43 | ||
| Q1 24 | — | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $172.1M | $12.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $61.0M | $40.2M |
| 总资产 | $258.3M | $53.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CHRSDMRC
| Q4 25 | $172.1M | $12.9M | ||
| Q3 25 | $191.7M | $12.6M | ||
| Q2 25 | $237.6M | $16.1M | ||
| Q1 25 | — | $21.6M | ||
| Q4 24 | — | $28.7M | ||
| Q3 24 | — | $33.7M | ||
| Q2 24 | $159.2M | $41.5M | ||
| Q1 24 | — | $48.9M |
股东权益CHRSDMRC
| Q4 25 | $61.0M | $40.2M | ||
| Q3 25 | $87.8M | $41.4M | ||
| Q2 25 | $119.8M | $46.5M | ||
| Q1 25 | — | $50.0M | ||
| Q4 24 | — | $61.4M | ||
| Q3 24 | — | $70.2M | ||
| Q2 24 | $-84.1M | $77.2M | ||
| Q1 24 | — | $84.5M |
总资产CHRSDMRC
| Q4 25 | $258.3M | $53.0M | ||
| Q3 25 | $516.5M | $55.4M | ||
| Q2 25 | $439.5M | $60.7M | ||
| Q1 25 | — | $66.5M | ||
| Q4 24 | — | $75.8M | ||
| Q3 24 | — | $85.0M | ||
| Q2 24 | $674.9M | $93.4M | ||
| Q1 24 | — | $99.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.7M | $991.0K |
| 自由现金流经营现金流 - 资本支出 | — | $895.0K |
| 自由现金流率自由现金流/营收 | — | 10.0% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-12.3M |
8季度趋势，按日历期对齐
经营现金流CHRSDMRC
| Q4 25 | $-19.7M | $991.0K | ||
| Q3 25 | $-46.3M | $-2.6M | ||
| Q2 25 | $-46.6M | $-4.7M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | — | $-7.1M | ||
| Q2 24 | $59.7M | $-6.8M | ||
| Q1 24 | — | $-8.4M |
自由现金流CHRSDMRC
| Q4 25 | — | $895.0K | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-4.9M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | — | $-7.2M | ||
| Q2 24 | — | $-6.9M | ||
| Q1 24 | — | $-8.5M |
自由现金流率CHRSDMRC
| Q4 25 | — | 10.0% | ||
| Q3 25 | — | -36.9% | ||
| Q2 25 | — | -61.0% | ||
| Q1 25 | — | -59.1% | ||
| Q4 24 | — | -49.1% | ||
| Q3 24 | — | -75.7% | ||
| Q2 24 | — | -66.1% | ||
| Q1 24 | — | -85.8% |
资本支出强度CHRSDMRC
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 1.1% |
现金转化率CHRSDMRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
